TLR agonists enhance hyperthermia-induced HSP synthesis.

1

Toll-like Receptor Agonists and Febrile-Range Hyperthermia Synergize to Induce Heat Shock Protein 70 Expression and Extracellular Release

Aditi Gupta1, Zachary A. Cooper1, Mohan E. Tulapurkar1, Ratnakar Potla1, Tapan Maity1, Jeffrey D.

Hasday1,2,3,4, and Ishwar S. Singh1,2,4

1From the Division of Pulmonary and Critical Care, Department of Medicine, 2Mucosal Biology Research Center, 3Cytokine Core Laboratory, University of Maryland School of Medicine, Baltimore, Maryland, USA

and the 4Research Services of the Baltimore Veteran Affairs Medical Center, Baltimore, Maryland, USA

*Running Title: TLR agonists enhance hyperthermia-induced HSP synthesis.

To whom correspondence should be addresses: Ishwar S. Singh, Ph.D., Division of Pulmonary and Critical Care, University of Maryland School of Medicine, Rm. 311, Health Science Facility-II, 20 Penn St., Baltimore, MD 21201. Phone: 410-706-5507, FAX: 410-706-5508, Email:isingh@umaryland.edu Keywords: Fever, hyperthermia, sepsis, Hsp70, HSF1 _______________________________________________________________________________________ Background: Inflammation and fever are coincident during various disease states including sepsis. Results: Co-exposure to inflammatory agonists during fever augments Hsp70 synthesis and extracellular release. Conclusion: Coincident activation of TLR signaling and heat shock response could be detrimental. Significance: The critical and complex interaction between inflammatory pathways and heat shock response pathway in the context of sepsis and shock. SUMMARY Heat shock protein (Hsp)-70 expression can be stimulated by febrile range temperature (FRT). Hsp70 has been shown to be elevated in serum of patients with sepsis and, when released from cells, extracellular Hsp70 exerts endotoxin-like effects through TLR (toll-like receptor)-4 receptors. Circulating TLR agonists and fever both persist for the first several days of sepsis and each can activate Hsp70 expression; however, the effect of combined exposure to FRT and TLR agonists on Hsp70 expression is unknown. We found that concurrent exposure to FRT (39.5°C) and agonists for TLR4 (LPS), TLR2 (Pam3Cys), or TLR3 (poly IC) synergized to increase Hsp70 expression and extracellular release in RAW264.7 macrophages. The increase in Hsp70 expression was associated with activation of p38 and ERK MAP kinases, phosphorylation of histone H3 and

increased recruitment of HSF1 to the Hsp70 promoter. Pretreatment with the p38 MAPK inhibitor SB283580 but not the ERK pathway inhibitor UO126 significantly reduced Hsp70 gene modification and Hsp70 expression in RAW cells co-exposed to LPS and FRT. In mice challenged with intratracheal LPS and then exposed to febrile range hyperthermia (core temperature ~39.5°C) Hsp70 levels in lung tissue and in cell-free lung lavage were increased compared with mice exposed to either hyperthermia or LPS alone. We propose a model of how enhanced Hsp70 expression and extracellular release in patients concurrently exposed to fever and TLR agonists may contribute to the pathogenesis of sepsis. ________________________________________ INTRODUCTION Engagement of host pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (PAMPs) activates a stereotypical immune response that includes fever, leukocytosis, and circulation of acute phase proteins (1). This immune response is critical for containment and eventual clearance of pathogens (1). Certain molecules of host origin, designated alarmins, can activate the same immune response. Alarmins typically perform important intracellular functions but when secreted through incompletely understood pathways or released from injured or dead cells, alarmins activate the same PRRs and the similar immune response as PAMPs (2).

http://www.jbc.org/cgi/doi/10.1074/jbc.M112.427336The latest version is at JBC Papers in Press. Published on December 4, 2012 as Manuscript M112.427336

Copyright 2012 by The American Society for Biochemistry and Molecular Biology, Inc.

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

2

Several candidate alarmins have been described, including high mobility group box 1 (HMGB1) (3), uric acid (4), mitochondrial DNA (5), and extracellular heat shock proteins (Hsps) (6,7). Hsp70 exhibits several properties that suggest it may be particularly important in the pathogenesis of sepsis. Although the role of Hsp70 as an alarmin is still debated (8), levels of Hsp70 in circulating leukocytes and in cell-free serum are elevated in sepsis and are associated with poor outcome (9-11). Extracellular Hsp70 can cause both early immune hyperactivation (7) and subsequent immunosuppression (12,13), two salient pathogenetic features of severe sepsis (14). Intracellular Hsp70 exerts multiple anti-apoptotic effects, including inhibition of JNK and p38 pathways (15), and recruitment of caspase-9 to the APAF-1-containing apoptosome (16). These effects can protect the structural integrity of cells but also augment the innate immune response by prolonging leukocyte survival (17). In eukaryotes, Hsps are transcriptionally regulated by the stress-activated transcription factor, heat shock factor-1 (HSF1) (18-20). In mammals, inactive monomeric cytosolic HSF1 is activated through an incremental process [Reviewed in (21)]. Exposure to stress activates HSF1 homotrimerization, which exposes a cryptic nuclear localization sequence and generates a composite DNA binding domain that promotes stable binding of the trimer to HSF1 binding element repeats in Hsp promoters. HSF1 trimerization and activation of its transactivation domain are regulated by multiple serine and threonine phosphorylation events. Transcription of Hsps is also influenced by other transcription factors, including STAT-1, STAT-3 and NF-IL-6 (22-24), tonicity enhancer binding protein and hypoxia-inducible factor-1 (25), and NFκB (26). We previously showed that HSF1 trimerization and Hsp70 transcription were activated in A549 cells by exposure to mild hyperthermia (38.5°C), that Hsp70 transcription increased as the exposure temperature increased from 38.5°C to 42°C, and that increased transcription was associated with additional HSF1 phosphorylation but not additional HSF1 trimerization (27). Hsp70 is expressed from two genes, HSPA1A and HSPA1B, that code for identical 461-amino acid sequences in humans (28). Endotoxin, killed streptococus, and other toll-like receptor (TLR) agonists have been shown to

activate Hsp70 expression in vitro (29) and in vivo (30). Since both fever (31) and endotoxemia (32) usually persist for the first several days of sepsis, afflicted patients are often concurrently exposed to these two stimuli for Hsp70 expression. However, to the best of our knowledge, the consequences of concurrent exposure to febrile-range temperature (FRT) and TLR agonists on Hsp70 expression and its extracellular release are unknown. The objective of this study was to test the hypothesis that TLR agonists and exposure to FRT synergize to increase expression and extracellular release of Hsps. We show that exposing mouse RAW 264.7 macrophages (RAW cells) to FRT (39.5°C) and TLR2 or TLR4 agonists synergize to increase both intracellular expression and extracellular release of Hsp70. We demonstrate that TLR2/4 agonists enhance FRT-induced Hsp70 expression by augmenting the p38-dependent recruitment and/or stabilization of HSF1 to the Hsp70 chromatin in association with phosphorylation of histone H3. We also show that concurrent exposure to febrile-range hyperthermia (core temperature ~39.5°C) and intratracheal instillation of LPS induce expression of Hsp70 in mouse lung and accumulation of cell-free Hsp70 in mouse lung lavage. We propose that extracellular release of Hsp70 during sepsis provides positive feedback through its TLR agonist activity that may contribute to the dysregulation of immune function in patients with severe sepsis. MATERIALS AND METHODS Reagents: LPS prepared by trichloroacetic acid extraction from Escherichia coli O111:B4 was purchased from Sigma-Aldrich (St. Louis, MO). TLR agonists Pam3Cys and poly IC were purchased from InvivoGen (San Diego, CA) and SB203580-hydrochloride and UO126 were obtained from EMD Biosciences (San Diego, CA). Mouse p38α (MAPK14) and negative control scrambled siRNA was obtained from Dharmacon. (Thermo Scientific, Lafayette, CO). Animals: Eight- to 10-wk-old male out bred CD-1 mice, weighing 25–30 g were purchased from Charles River, housed in the Baltimore Veterans Administration Medical Center animal facility under American Association of Laboratory

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

3

Animal Care-approved conditions and under the supervision of a full-time veterinarian. All animals were used within 4 wk of delivery. All protocols were approved by the Institutional Animal Care and Use Committee of the University of Maryland and the Animal Use Sub-committee at the Baltimore VA Medical Center. Hyperthermia and LPS challenge: Mice were adapted to standard plastic cages for at least 4 days before study. To avoid the influence of diurnal cycling, all experiments were started at approximately the same time each day (between 8:00 and 10:00 a.m.). One sentinel mouse per experimental group was implanted with an intraperitoneal telemetric thermistor (Data Safety International; St. Paul, MN; ETA-F10) as we have previously described (33,34) and allowed to recover for 7 days prior to further experimentation. Exposure to hyperthermia and LPS challenge and core temperature monitoring was performed as described in our previous studies (33,34). Briefly, cages containing two mice per cage were transferred into modified Air Shields™ infant incubators set to 36-37°C. Normothermic controls were handled and housed in the same way except at standard room temperature (24-25°C). In conscious unrestrained mice, such exposures maintain core temperatures of 39.5–40°C and 36.5–37°C, respectively (33,34). For LPS instillation, mice were briefly anesthetized with isoflurane and 50 µg of LPS in 50 µl phosphate buffered saline (PBS) was administered into the posterior pharynx with the tongue retracted until aspiration was witnessed. Twenty four hours later, the mice were euthanized by isoflurane inhalation and cervical dislocation and either lungs were resected and frozen in liquid nitrogen for homogenization in RIPA buffer or lung lavage was performed with a total of 2 ml PBS as we have previously described (33,35,36). Cell culture: RAW cells and the human lung epithelial-like A549 cell lines were maintained in RPMI 1640 supplemented with 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer (Gibco/Invitrogen, Carlsbad, CA), pH 7.3 (CRPMI) and 10% defined fetal bovine serum (FBS; Gibco/Invitrogen, Carlsbad, CA) (Complete RPMI). Cells were routinely tested

for Mycoplasma infection using a commercial assay system (MycoTest, Invitrogen), and new cultures were established monthly from frozen stocks. Cell viability was determined by trypan blue dye exclusion. Cells were treated with agonists and signaling inhibitors as indicated and incubated continuously at 37°C (normothermia) or 39.5°C (FRT) or heat shocked (HS) by exposing to 42°C for 2h, then returning to 37°C using automatic CO2 incubators certified to have <0.2°C temperature variation (Forma; Marietta, OH) and calibrated for each experiment using an electronic thermometer (FLUKE Instruments model 5211, Everett, WA). Supernatants were collected, clarified by centrifugation at 15,000xg and analyzed for Hsp70 by ELISA using a DuoSet IC Total Hsp70 ELISA Kit (R & D Systems; Minneapolis, MN) at the University of Maryland Cytokine Core Laboratory on campus. The assay had a lower detection limit of 156 pg/ml. Cells were washed with PBS, then lysed in RIPA buffer for immunoblotting. Immunoblotting: Lung homogenates or cell extracts were prepared in RIPA buffer containing protease and phosphatase inhibitors (Roche Diagnostics; Indianapolis, IN), clarified by centrifugation at 15,000xg, and protein was assayed using the Bradford method (Biorad; Hercules, CA) using a bovine serum albumin standard curve. Sample containing 20 µg total protein was resolved by SDS-PAGE, electrostatically transferred to polyvinylidene difluoride membrane for immunoblotting. For 2-dimensional gel electrophoresis, about 100 µg of total protein from cell extracts was resuspended in 2-D sample buffer (Biorad) and was resolved on the first dimension on a ZOOM® IPG Runner System (Invitrogen) using immobilized pH 3–10 gradient IPG strip (Invitrogen). The strip was then resolved in the second dimension using a NuPAGE® Novex 4-12% gel (Invitrogen) and the resolved proteins were transferred to PVDF membranes. For immunoblotting, the membranes were blocked with 5% nonfat dry milk in TTBS (25 mM Tris pH 7.4, 0.5M NaCl, 0.05% Tween-20) and probed using the following antibodies: Hsp70 (StressGen; Ann Arbor, MI), β-tubulin (Millipore/Chemicon; Bellerica, MA), HSF-1, phospho-ERK, phospho-ribosome S6 kinase (RSK) and their total forms from Santa Cruz Biotechnology (Santa Cruz, CA) and total and

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

4

p38α, phospho-p38 and phospho-MAP kinase-activated protein kinase-2 (MK2) were obtained from Cell Signaling (Danvers, MA). Bands developed using HRP-conjugated appropriate secondary antibody (SantaCruz) and ECL detection system (Pierce, Thermo Fisher), and quantified using a gel documentation system (Fuji LAS-4000) as described earlier (33,36,37). RNA Extraction and quantitative real-time PCR: Total RNA from RAW cells was isolated using a Qiagen kit (Valencia, CA), contaminating DNA eliminated using DNase I digestion and RNA was reverse-transcribed using oligo-dT primers and a cDNA synthesis kit according to the manufacturer’s protocol (Promega; Madison, WI) as we have previously described (36,37). Duplicate 25 µl real-time PCR reactions were performed in 96 well plates using a SYBR-Green reaction mix (BioRad) and a BioRad iCycler IQ Optical Module according to the supplier’s protocol with the following forward and reverse primers: glyceraldehydes-3-phosphate dehydrogenase (GAPDH), 5’-agcctcgtcccgtagacaaaat and 5’-tggcaacaatctccactttgc; HSPA1A, 5’-ggccagggctggattact and 5’-gcaaccaccatgcaagatta. Data were quantified using the Gene Expression Ct Difference method and standardized to levels of the housekeeping gene, GAPDH, using Ct values automatically determined by the thermocycler (36,37). Electrophoretic Mobility Shift Assay: Nuclear extracts were prepared according to the method of Schreiber et al. (38) as described earlier (37,39) and total protein concentration measured. Double-stranded oligonucleotides containing the consensus HSF1 binding sequence from the human Hsp-70 promoter 5′-GATCTCGGCTGGAATATTCCCGACCTGGCAGCCGA-3′ and the complementary strands were synthesized, annealed, and were radiolabeled with [32γP]ATP using T4 polynucleotide kinase (Promega) according to the manufacturer's protocol (37,39). Twenty microliter EMSA reactions containing 5 µg nuclear extract, 0.035 pmol radiolabeled oligonucleotide, 1 µg poly IC, 10 mM Tris-HCl, pH 7.8, 10% glycerol, 60 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol were incubated at room temperature for 30 min. For supershift

and competetion assays, the reaction mixture was pre-incubated on ice for 30 min with either 0.5 µg rabbit IgG or anti HSF1 antibody (SantaCruz) or with 10x cold probe or a non specific double-stranded oligonucleotide, respectively, prior to the incubation with radiolabeled oligonucleotide probe (37,39,40). The DNA·protein complexes were electrophoretically resolved on 4% nondenaturing polyacrylamide gels. The dried gels were analyzed by phosphorimaging (Molecular Dynamics; Sunnyvale, CA) and subsequently exposed to x-ray film. Chromatin Immunoprecipitation (ChIP) assays: ChIP assays were performed using a kit from Millipore/Upstate Biotechnology as described previously (36,37,39). In brief, RAW cells were treated as indicated, cross-linked using 1% formaldehyde for 15 min, washed with PBS, and collected by centrifugation. The cell pellets were re-suspended in SDS lysis buffer and sonicated for three 10 sec bursts using a Branson Sonifier 450 (duty cycle and output settings were 30 and 3, respectively). Sonicated cell lysates were diluted 10-fold using ChIP dilution buffer and precleared for 1 h at 4°C using 80 µl of a 50% salmon sperm DNA-saturated protein A agarose beads. Cross-linked chromatin was immunoprecipitated with either control IgG or using specific antibodies as indicated at 4°C overnight, immune complexes collected and cross-linked protein-DNA was reverted by incubating at 65°C for 4 h. DNA was extracted and used as template for real-time PCR as described earlier (36,41). Primer pairs spanning the HRE binding site on the HSPA1A promoter (forward 5’-agcaccagcacttccccaca and reverse 5’-ccgctgggccaatcagcgag) were used and fold enrichment with specific antibody against non-specific antibody was determined as described previously (36,41). siRNA Transfections: siRNA targeted against mouse p38α (MAPK14) and negative control scrambled siRNA was obtained from Dharmacon. (Thermo, Lafayette, CO). RAW cells (2x106) were transfected with the RNA duplexes using the Amaxa Nucleofector Kit V and Nucleofector 2b device (Lonza, Allendale, NJ) and the cells were plated in 12-well plates at 250,000 cells per well. 48h after transfection the cells were either immunoblotted for p38α expression or stimulated with or without LPS as indicated and analyzed for

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

5

Hsp70 expression in cell lysates by immunoblotting. Cytotoxicity Assay: The cytotoxic effect of hyperthermia and LPS exposure was analyzed by measuring lactate dehydrogenase (LDH) release using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega). Statistical analysis: Data are displayed as mean ± SE. Differences between two groups were analyzed by unpaired Student t-test and among multiple groups was analyzed by applying a Tukey-Kramer honestly significant difference test to a one-way ANOVA. Differences with p < 0.05 were considered significant. RESULTS LPS and other proinflammatory agonists enhance hyperthermia-induced Hsp70 expression in primary and tissue culture cells: In RAW cells exposed to FRT for 4 h, Hsp70 mRNA levels were 14-fold greater than cells incubated at 37°C. Treatment with 100 ng/ml LPS did not increase Hsp70 mRNA levels in RAW cells incubated at 37°C but when combined with FRT, increased Hsp70 mRNA levels ~50-fold compared with untreated 37°C cells (fig 1a). Exposing RAW cells to FRT for 6 h stimulated a modest increase in cell-associated Hsp70 protein levels but much less compared with cells exposed to HS (42°C for 2 h followed by 4 h recovery at 37°C (compare lane 2 in fig 1b, c). Stimulating RAW cells with LPS or an agonist for TLR1/2 (Pam3cys) stimulated a profound increase in Hsp70 protein in both FRT- and HS-exposed RAW cells. The TLR3 agonist, poly IC, exerted similar effects in FRT- and HS-exposed RAW cells albeit of lesser magnitude than LPS and Pam 3cys. In human lung epithelial-like A549 cells treatment with IL-1β enhanced Hsp70 expression in cells incubated at 39.5°C but not 37°C (fig 1d). Effect of TLR agonists on HSF1 phosphorylation: We analyzed whether TLR agonists stimulated posttranslational modification of HSF1 protein by treating RAW cells with TLR agonists and assessing electrophoretic mobility of HSF1 on immunoblots (fig 2a). A decrease in HSF1 band

mobility was evident within 5 min of LPS treatment, persisted for 30 min, returned to baseline by 60 min, and remained at baseline levels for the remainder of the 24h incubation (data or not shown). To confirm the mobility shift was due to HSF1 phosphorylation, we incubated LPS-treated RAW cell extracts with shrimp alkaline phosphatase (SAP) for 30 min, which reduced the shift in HSF1 toward baseline levels exhibited by untreated control cells (fig 2b). Additionally, 2 dimensional gel analysis and HSF1 immunoblotting of cell extracts from LPS-treated RAW cells showed a mobility shift toward lower pH as is typical of protein phosphorylation (fig 2c). To determine whether activating HSF1 phosphorylation was a property unique to LPS/TLR4 or was shared by agonists of other TLRs, we analyzed HSF1 mobility in 37°C RAW cells stimulated for 30 min with agonists for TLR2 and 3 in the presence or absence of polymyxin B to exclude contamination with LPS. As expected treating RAW cells with LPS reduced HSF1 mobility and this effect was blocked by co-treatment with polymyxin B (fig 2d). Treatment with the TLR1/2 agonist, Pam3CSK4, caused a similar decrease in HSF1 mobility, but the effect persisted in the presence of polymyxin B, excluding a contribution from contaminating endotoxin. In contrast, the TLR3 agonist, poly IC, did not stimulate a detectable shift in HSF1 mobility. Effect of co-exposure to LPS and FRT on in vitro HSF1-DNA binding activity and recruitment of HSF1 to the Hsp70 chromatin in RAW cells: We analyzed whether treatment with LPS enhanced HSF1 DNA binding activity in RAW cells at 37° and 39.5°C. RAW cells were incubated with or without 100 ng/ml LPS at 37° or 39.5°C for 30 or 60 min and nuclear extracts analyzed for DNA-binding-capable HSF1 trimers by EMSA using a consensus HSF1 binding sequence (36,37,39). As expected, DNA-binding-capable HSF1 was detectable in untreated RAW cells incubated at 39.5°C but not in cells incubated at 37°C (fig 3a). Competition with cold probe and supershift with anti-HSF1 antibody established the identified band to be HSF1 (fig 3b). LPS treatment did not increase nuclear levels of DNA-binding HSF1 at either temperature. We used a ChIP assay to determine whether treatment

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

6

with LPS stimulated specific recruitment of HSF1 to the HSPA1A promoter. As expected, incubating RAW cells for 60 min increased HSF1 recruitment to the HSF1 chromatin by ~6 fold (p<0.05) compared with 37°C control cells, but surprisingly, concurrent treatment with LPS stimulated an additional >2-fold increase in HSF1 recruitment to Hsp70 chromatin in RAW cells incubated at 39.5°C (p<0.05) (fig 3c). LPS treatment increased histone H3 phosphorylation at the Hsp70 chromatin in RAW cells at FRT: Since treating RAW cells with LPS increased HSF1 recruitment to Hsp70 chromatin without increasing global nuclear levels of activated HSF1, we asked whether LPS treatment induces chromatin modification on the Hsp70 promoter that might increase its accessibility to HSF1. Because previous studies showed that exposure to heat shock maximally stimulated acetylation of histone H4 associated with the mouse Hsp70 promoter (42), we considered other potential chromatin modifications by which LPS augments Hsp70 expression. Treatment with arsenic activates Hsp70 transcription by stimulating both histone H4 acetylation and histone H3 phosphorylation, whereas exposure to heat shock alone only stimulated H4 acetylation (42). We used a ChIP assay to analyze the phosphorylation of histone H3 10Ser on Hsp70 promoter in RAW cells incubated with or without LPS at 37° or 39.5°C (Fig. 4a). Histone H3 phosphorylation on the HSF1 binding region of HSPA1A was similar in RAW cells incubated at 37°C with or without LPS or at 39.5°C without LPS for 60 min. However, co-exposure to 39.5°C and LPS stimulated a 4.2-fold increase in histone H3 phosphorylation without any apparent change in total Histone H3 enrichment in the same region of the Hsp70 promoter (fig 4b). Immunoblotting for phosphorylated forms of p38 and ERK showed that LPS treatment of RAW cells stimulated both p38 and ERK activation (fig 4c). We then used pharmacologic inhibitors of ERK (U0126) and p38 (SB203580) to examine the effects of inhibiting these pathways. First we confirmed that the inhibitors effectively blocked the appropriate signaling pathway by pretreating RAW cells with U0126 or SB203580, then stimulating with LPS for 30 min at 39.5°C and immunoblotting for the ERK and p38 substrates,

phosphorylated RSK and MK2 (Fig. 4d). Treatment with U0126 eliminated the phosphorylated RSK2 but had no effect on MK2. MK2 phosphorylation as indicated by both the intensity of the phosphorylated MK2 band and the reduced electrophoretic mobility of both the phosphorylated and total MK2 bands was reduced by SB203580 treatment while RSK phosphorylation was unaffected. To analyze the effects of p38 and ERK pathway inhibition, we pretreated RAW cells with the inhibitors or DMSO (vehicle) for 30 min and then stimulated the cells with LPS at 39.5oC for 2h or 6h for analysis of RNA and protein, respectively. Treatment with SB203580 significantly blocked the increase in Hsp70 mRNA (fig 4e) and protein generation (fig 4f) in comparison to cells pretreated with DMSO in cells co-exposed to LPS at FRH. While LPS also activated ERK (4c), treatment with the ERK inhibitor, U0126, did not block incremental Hsp70 expression in RAW cells co-treated with LPS and FRT (Fig. 4e, f). Furthermore, a ChIP assay for phosphorylated histone H3 in the presence of SB203580 showed that p38 inhibition significantly reduced histone H3 phosphorylation in LPS-treated RAW cells at FRT (fig 4g). To further analyze the role of p38, we used siRNA to knockdown p38α. RAW cells were transfected with either scrambled negative control siRNA of p38α siRNA and after 48h of transfection the cells were immunoblotted for p38α expression to confirm depletion of p38α protein levels (fig 5a). When the siRNA trasfected cells were stimulated with or without LPS at FRT, Hsp70 expression was significantly increased in control siRNA transfected cells but not in cells transfected with 50 or 100 pM p38α siRNA (fig 5b, c). LPS challenge increased release of extracellular Hsp70: To begin to understand the consequences of the enhanced Hsp70 expression following co-exposure to LPS and FRT, we also analyzed the effect of LPS and hyperthermia on release of Hsp70 into the extracellular microenvironment where it can exert proinflammatory TLR4 agonist activity (7,43). RAW cells were incubated with 0, 100, or 1000 ng/ml LPS at 37°C or 39.5°C or were exposed to a concurrent 2h 42°C HS and culture supernatants were collected after 6 and 24

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

7

h and analyzed for Hsp70 by ELISA. In the absence of LPS, incubation at 39.5°C for 6 or 24 h failed to stimulate Hsp70 release, but cells stimulated with LPS at 39.5°C significantly increased Hsp70 release at both doses of LPS (fig 6a, b). In contrast, RAW cells exposed to HS released substantially more Hsp70 even in the absence of LPS treatment (fig 6c and d), but treating with LPS further increased the release of Hsp70 in the culture supernatants. To distinguish between active Hsp70 secretion and leak from dead or dying cells, we also measured LDH in the culture supernatant. Accumulation of extracellular Hsp70 was accompanied by LDH release in cells exposed to HS, but occurred without detectable LDH release in cells treated with LPS at 39.5°C (fig. 6e). Intratracheal LPS challenge enhanced Hsp70 expression in lung of hyperthermic mice: As we have previously shown (33,34), mice housed at 36°-37°C ambient temperature increased their core temperature by ~2.5°C to 39-40°C and maintained the same activity level and Circadian temperature pattern as in normothermic mice (fig 7a). Immunoblotting of lung homogenates showed ~110% increase in mice exposed to hyperthermia and a further 68% increase when hyperthermic mice were challenged with intratracheal LPS (fig 7b). However, LPS challenge failed to stimulate an increase in lung-associated Hsp70 protein levels in normothermic mice. To determine whether LPS exerts similar effects on Hsp70 release in vivo, we used ELISA to analyze Hsp70 levels in cell-free lung lavage from mice exposed to hyperthermia and intratracheal LPS instillation alone and in combination. Neither LPS instillation nor hyperthermia alone stimulated significant changes in lung lavage Hsp70 levels, but the combination of LPS instillation and hyperthermia exposure for 24 h stimulated over a 2-fold increase in Hsp70 concentration compared with untreated normothermic mice (fig 7c). DISCUSSION We have previously shown that exposure to FRT (38.5-39.5°C) is sufficient to activate HSF1 and induce expression of Hsp70 but at much lower levels than occurs in response to

temperatures above 42°C (27,40). In the current study, we have extended these findings by showing that stimulating TLR-dependent signaling pathways while exposing cells to FRT or HS greatly augments Hsp70 expression and its release into the extracellular microenvironment in both in vitro cell culture and in vivo in an intratracheal LPS-induced acute lung injury model. We used RAW 264.7, an Abelson murine leukemia virus-transformed macrophage cell line that exhibits macrophage morphology and function and expresses all TLRs except TLR5 (44). We showed that exposing RAW cells to 39.5°C for 2 to 4 h increased Hsp70 mRNA levels 7- to 15-fold. In an earlier study, we found that exposing RAW cells to 40°C failed to activated Hsp70 mRNA expression (45) but the cells were only heated for 30 min in the previous study. The results of the two studies are consistent with our observation that Hsp70 induction at less extreme hyperthermia requires longer exposure time (27). In the present study, we showed that co-treating RAW cells with TLR4 (LPS) or TLR2/1 (Pam3cys) agonists greatly augmented Hsp70 expression in FRT-exposed RAW cells. The TLR3 agonist, poly IC, exerted a smaller effect on Hsp70 expression. Treating A549 human lung epithelial-like cells with IL-1ß stimulated a similar increase in Hsp70 expression at FRT. TLR2 and 4 and the IL-1 receptor share the same MyD88-dependent signaling pathway whereas TLR3 activates a distinct, MyD88-independent signaling pathway (46,47). Both signaling pathways activate NFκB and MAP kinases, although activation of these signaling elements is indirect and delayed in MyD88-independent signaling, which may be responsible for the lower Hsp70 inducing activity of poly IC. Since the transcriptional activation of Hsp genes is regulated by the stress-activated transcription factor, HSF1, which itself is regulated by posttranslational modification including phosphorylation (18,48,49), we analyzed whether the TLR agonists stimulated post-translational modification of HSF1. We found that RAW cells stimulated with TLR1/2 and TLR 4 agonists at 37°C caused a distinct shift in HSF1 mobility on SDS and on 2D-gels (fig 2), consistent with an increase in HSF1 phosphorylation (40,48,50). However, the apparent phosphorylation of HSF1 by LPS in

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

8

37°C RAW cell cultures was transient, lasting only 30 min, and was not associated with either HSF1 activation as assessed by EMSA (fig 3a) or induction of Hsp70 expression (fig 1). Analysis of the interaction of HSF1 with the Hsp70 promoter in vivo by ChIP assay demonstrated that LPS treatment doubled the recruitment of HSF1 to the Hsp70 chromatin in FRT-exposed RAW cells (fig 3c). Collectively, these results suggest that TLR agonists may enhance Hsp70 expression through specific effects on the HPS70 gene rather than through global modification of HSF1. Transcriptional activation of Hsp70 is critically regulated by chromatin architecture and histone modifications (51-55), some of which are mediated through activation of MAP kinase cascades. The MAP kinase, p38, has been implicated in activation of Hsp gene transcription activated by cadmium and arsenic (42,56) but not by HS or low pH (42,56,57). In fact, Thomson et al. (42) showed that arsenic treatment increased p38 activation, histone phosphorylation and enrichment of phospho-histone H3 at the Hsp70 chromatin and that arsenic-induced histone H3 phosphorylation and Hsp70 transcription was sensitive to p38 inhibitors. LPS and other TLR agonists are known to activate MAP kinase signaling and we have earlier shown that p38 MAPK is activated by LPS to comparable levels at 37° and 39.5°C (36). ChIP assays using an antibody that recognizes histone H3 phosphorylated on 10Ser showed that co-treatment with LPS and FRT increased enrichment of phospho-histone H3 on the HSF1-binding region of the HSPA1A promoter (fig 4a) coincident with recruitment of HSF1 to the same region (fig 3c). Phosphorylation of 10Ser on histone H3 was the same modification shown to accompany the increase in arsenic-induced Hsp70 expression in NIH 3T3 fibroblasts (42). ERK and p38 are each activated following LPS treatment in RAW cells (36) and both kinases can stimulate phosphorylation of histone H3 through activation of MSK1 and 2 (58,59). Park et al. (60) showed that treating RAW cells with LPS also stimulates histone H3 phosphorylation on cyclooxygenase 2-associated chromatin and activates cyclooxygenase expression, both of which were blocked by the p38 inhibitor SB203580. Histone H3 phosphorylation on Hsp70 in arsenic-treated NIH 3T3 fibroblasts was also associated with p38 activation and blocked by SB203580 (42). We

found that pretreating RAW cells with the p38 MAP kinase inhibitor, SB203580, reduced the effect of LPS and FRT on HSPA1A-associated histone H3 phosphorylation (fig 4g) and Hsp70 mRNA and protein (fig 4e, f)) expression. To further analyze the role of p38-mediated signaling we use siRNA to knockdown p38α. Since SB203580 is known to only inhibit p38α and β isoforms and because p38α is the major isoform that is activated in inflammatory cells (61) we focused first on p38α. Interestingly, p38α depletion reduced LPS-activated Hsp70 expression in cells exposed to FRT (fig 5b, c). These results suggest that p38 (primarily p38α) or one of its downstream targets participates in LPS-induced phosphorylation of histone H3 on the Hsp70 chromatin, recruitment of HSF1, and transcriptional activation of Hsp70. However, we have not excluded the contribution of additional HSF1 and histone modifications including HSF1 sumoylation (62,63) and histone acetylation and methylation (42,49,54,64). Considering that co-exposure to TLR agonists and FRT is likely to occur in human sepsis (31,32), the results of this study suggest a possible positive feedback amplification pathway that may contribute to severe sepsis (fig 8). In addition to the established role as cytoprotective molecules and chaperone proteins, Hsps and Hsp70 in particular, have more recently been detected in the extracellular milieu and have been appreciated as potential alarmins that signal through TLRs (43,65,66). Although there was an earlier debate about whether the TLR agonist activity of HSP70 was the result of its contamination by bacterial products (8,67,68), use of recombinant Hsp70 isolated from insect cells, non-recombinant Hsp70, boiled or polymyxin B treated Hsp70 have provided convincing evidence that Hsp70 has intrinsic TLR agonist activity and can activate macrophages, monocytes, dendritic cells and natural killer cells (12,65,69-75). Clinical studies show that Hsp70 levels in circulating leukocytes and serum are elevated in sepsis and are associated with poor outcome (9-11). Moreover, studies with human immune cells show that extracellular Hsp70 can cause both early immune hyperactivation (7) and delayed immunosuppression (12,13), two salient pathogenetic features of severe sepsis (14). If LPS and fever stimulate expression and extracellular release of Hsp70, the Hsp70 itself

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

9

may synergize with fever to sustain the proinflammatory state through its TLR4 agonist activity (7) and stimulate additional Hsp70 expression. In addition, persistent exposure to Hsp70 may cause cross-tolerance to other TLR agonists, including endotoxin (12,13), which may increase susceptibility to secondary infections. The association of elevated serum Hsp70 levels and mortality in sepsis is consistent with such a model. In summary, we have shown that co-exposure to TLR agonists and febrile range hyperthermia

greatly augments Hsp70 synthesis and extracellular release at least in part through the increased recruitment of HSF1 to the Hsp70 chromatin following p38-dependent phosphorylation of associated histone H3. The results suggest that the TLR agonist activity of extracellular Hsp70 may worsen sepsis and suggests a potential benefit of maintaining normothermia in patients with sepsis. However, the ultimate effect of fever suppression in sepsis awaits empiric evidence from clinical trials.

REFERENCES 1. Sriskandan, S., and Altmann, D. M. (2008) The immunology of sepsis. J Pathol 214, 211-

223 2. Bianchi, M. E. (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J

Leukoc Biol 81, 1-5 3. Andersson, U., Wang, H., Palmblad, K., Aveberger, A. C., Bloom, O., Erlandsson-Harris,

H., Janson, A., Kokkola, R., Zhang, M., Yang, H., and Tracey, K. J. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192, 565-570

4. Shi, Y., Evans, J. E., and Rock, K. L. (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521

5. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., and Hauser, C. J. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107

6. Ohashi, K., Burkart, V., Flohe, S., and Kolb, H. (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164, 558-561

7. Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Bare, O., Auron, P. E., Stevenson, M. A., and Calderwood, S. K. (2002) Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 277, 15028-15034

8. van Eden, W., Spiering, R., Broere, F., and van der Zee, R. (2011) A case of mistaken identity: HSPs are no DAMPs but DAMPERs. Cell Stress Chaperones 17, 281-292

9. Gelain, D. P., de Bittencourt Pasquali, M. A., C, M. C., Grunwald, M. S., Ritter, C., Tomasi, C. D., Alves, S. C., Quevedo, J., Dal-Pizzol, F., and Moreira, J. C. (2011) Serum heat shock protein 70 levels, oxidant status, and mortality in sepsis. Shock 35, 466-470

10. Wheeler, D. S., Fisher, L. E., Jr., Catravas, J. D., Jacobs, B. R., Carcillo, J. A., and Wong, H. R. (2005) Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med 6, 308-311

11. Hashiguchi, N., Ogura, H., Tanaka, H., Koh, T., Nakamori, Y., Noborio, M., Shiozaki, T., Nishino, M., Kuwagata, Y., Shimazu, T., and Sugimoto, H. (2001) Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. J Trauma 51, 1104-1109

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

10

12. Aneja, R., Odoms, K., Dunsmore, K., Shanley, T. P., and Wong, H. R. (2006) Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. J Immunol 177, 7184-7192

13. Abboud, P. A., Lahni, P. M., Page, K., Giuliano, J. S., Jr., Harmon, K., Dunsmore, K. E., Wong, H. R., and Wheeler, D. S. (2008) The role of endogenously produced extracellular hsp72 in mononuclear cell reprogramming. Shock 30, 285-292

14. Rittirsch, D., Flierl, M. A., and Ward, P. A. (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8, 776-787

15. Park, H. S., Cho, S. G., Kim, C. K., Hwang, H. S., Noh, K. T., Kim, M. S., Huh, S. H., Kim, M. J., Ryoo, K., Kim, E. K., Kang, W. J., Lee, J. S., Seo, J. S., Ko, Y. G., Kim, S., and Choi, E. J. (2002) Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 22, 7721-7730

16. Beere, H. M., Wolf, B. B., Cain, K., Mosser, D. D., Mahboubi, A., Kuwana, T., Tailor, P., Morimoto, R. I., Cohen, G. M., and Green, D. R. (2000) Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2, 469-475

17. Oehler, R., Pusch, E., Zellner, M., Dungel, P., Hergovics, N., Homoncik, M., Eliasen, M. M., Brabec, M., and Roth, E. (2001) Cell type-specific variations in the induction of hsp70 in human leukocytes by fever like whole body hyperthermia. Cell Stress Chaperones 6, 306-315

18. Pirkkala, L., Nykanen, P., and Sistonen, L. (2001) Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. Faseb J 15, 1118-1131

19. Morimoto, R. I. (1993) Cells in stress: transcriptional activation of heat shock genes. Science 259, 1409-1410

20. Christians, E. S., Yan, L. J., and Benjamin, I. J. (2002) Heat shock factor 1 and heat shock proteins: critical partners in protection against acute cell injury. Crit Care Med 30, S43-50

21. Singh, I. S., Shah, N. G., Almutairy, E. A., and Hasday, J. D. (2009) Role of HSF1 in Infectious Disease. in Prokaryotic and Eukaryotic Heat Shock Proteins in Infectious Disease (Pockley, A. G., Santoro, M. G., and Calderwood, S. K. ed.), Springer Netherlands. pp 1-31

22. Stephanou, A., Isenberg, D. A., Nakajima, K., and Latchman, D. S. (1999) Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem 274, 1723-1728

23. Stephanou, A., Isenberg, D. A., Akira, S., Kishimoto, T., and Latchman, D. S. (1998) The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways co-operate to mediate the activation of the hsp90beta gene by interleukin-6 but have opposite effects on its inducibility by heat shock. Biochem J 330 ( Pt 1), 189-195

24. Magalhaes, F. C., Passos, R. L., Fonseca, M. A., Oliveira, K. P., Ferreira-Junior, J. B., Martini, A. R., Lima, M. R., Guimaraes, J. B., Barauna, V. G., Silami-Garcia, E., and Rodrigues, L. O. (2010) Thermoregulatory efficiency is increased after heat acclimation in tropical natives. J Physiol Anthropol 29, 1-12

25. Gogate, S. S., Fujita, N., Skubutyte, R., Shapiro, I. M., and Risbud, M. V. (2012) Tonicity enhancer binding protein (TonEBP) and hypoxia-inducible factor (HIF) coordinate heat shock protein 70 (Hsp70) expression in hypoxic nucleus pulposus cells: role of Hsp70 in HIF-1alpha degradation. J Bone Miner Res 27, 1106-1117

26. Wilhide, M. E., Tranter, M., Ren, X., Chen, J., Sartor, M. A., Medvedovic, M., and Jones, W. K. (2011) Identification of a NF-kappaB cardioprotective gene program: NF-kappaB regulation of Hsp70.1 contributes to cardioprotection after permanent coronary occlusion. J Mol Cell Cardiol 51, 82-89

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

11

27. Tulapurkar, M. E., Asiegbu, B. E., Singh, I. S., and Hasday, J. D. (2009) Hyperthermia in the febrile range induces HSP72 expression proportional to exposure temperature but not to HSF-1 DNA-binding activity in human lung epithelial A549 cells. Cell Stress Chaperones

28. Milner, C. M., and Campbell, R. D. (1990) Structure and expression of the three MHC-linked HSP70 genes. Immunogenetics 32, 242-251

29. Fincato, G., Polentarutti, N., Sica, A., Mantovani, A., and Colotta, F. (1991) Expression of a heat-inducible gene of the HSP70 family in human myelomonocytic cells: regulation by bacterial products and cytokines. Blood 77, 579-586

30. Zhang, Y. H., Takahashi, K., Jiang, G. Z., Zhang, X. M., Kawai, M., Fukada, M., and Yokochi, T. (1994) In vivo production of heat shock protein in mouse peritoneal macrophages by administration of lipopolysaccharide. Infect Immun 62, 4140-4144

31. Cunha, B. A. (1999) Fever in the intensive care unit. Intensive Care Med 25, 648-651 32. Guidet, B., Barakett, V., Vassal, T., Petit, J. C., and Offenstadt, G. (1994) Endotoxemia and

bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 106, 1194-1201 33. Tulapurkar, M. E., Hasday, J. D., and Singh, I. S. (2011) Prolonged exposure to

hyperthermic stress augments neutrophil recruitment to lung during the post-exposure recovery period. Int J Hyperthermia 27, 717-725

34. Sareh, H., Tulapurkar, M. E., Shah, N. G., Singh, I. S., and Hasday, J. D. (2011) Response of mice to continuous 5-day passive hyperthermia resembles human heat acclimation. Cell Stress Chaperones 16, 297-307

35. Rice, P., Martin, E., He, J. R., Frank, M., DeTolla, L., Hester, L., O'Neill, T., Manka, C., Benjamin, I., Nagarsekar, A., Singh, I., and Hasday, J. D. (2005) Febrile-range hyperthermia augments neutrophil accumulation and enhances lung injury in experimental gram-negative bacterial pneumonia. J Immunol 174, 3676-3685

36. Cooper, Z. A., Ghosh, A., Gupta, A., Maity, T., Benjamin, I. J., Vogel, S. N., Hasday, J. D., and Singh, I. S. (2010) Febrile-range temperature modifies cytokine gene expression in LPS-stimulated macrophages by differentially modifying NF-{kappa}B recruitment to cytokine gene promoters. Am J Physiol Cell Physiol 298, C171-181

37. Singh, I. S., Gupta, A., Nagarsekar, A., Cooper, Z., Manka, C., Hester, L., Benjamin, I. J., He, J. R., and Hasday, J. D. (2008) Heat shock co-activates interleukin-8 transcription. Am J Respir Cell Mol Biol 39, 235-242

38. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17, 6419

39. Singh, I. S., He, J. R., Calderwood, S., and Hasday, J. D. (2002) A high affinity HSF-1 binding site in the 5'-untranslated region of the murine tumor necrosis factor-alpha gene is a transcriptional repressor. J Biol Chem 277, 4981-4988

40. Singh, I. S., Viscardi, R. M., Kalvakolanu, I., Calderwood, S., and Hasday, J. D. (2000) Inhibition of tumor necrosis factor-alpha transcription in macrophages exposed to febrile range temperature. A possible role for heat shock factor-1 as a negative transcriptional regulator. J Biol Chem 275, 9841-9848

41. Maity, T. K., Henry, M. M., Tulapurkar, M. E., Shah, N. G., Hasday, J. D., and Singh, I. S. (2011) Distinct, gene-specific effect of heat shock on heat shock factor-1 recruitment and gene expression of CXC chemokine genes. Cytokine 54, 61-67

42. Thomson, S., Hollis, A., Hazzalin, C. A., and Mahadevan, L. C. (2004) Distinct stimulus-specific histone modifications at hsp70 chromatin targeted by the transcription factor heat shock factor-1. Mol Cell 15, 585-594

43. Calderwood, S. K., Mambula, S. S., Gray, P. J., Jr., and Theriault, J. R. (2007) Extracellular heat shock proteins in cell signaling. FEBS Lett 581, 3689-3694

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

12

44. Applequist, S. E., Wallin, R. P., and Ljunggren, H. G. (2002) Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol 14, 1065-1074

45. Ensor, J. E., Crawford, E. K., and Hasday, J. D. (1995) Warming macrophages to febrile range destabilizes tumor necrosis factor-alpha mRNA without inducing heat shock. Am J Physiol 269, C1140-1146

46. Vogel, S. N., Fitzgerald, K. A., and Fenton, M. J. (2003) TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol Interv 3, 466-477

47. Takeda, K., Kaisho, T., and Akira, S. (2003) Toll-like receptors. Annu Rev Immunol 21, 335-376

48. Guettouche, T., Boellmann, F., Lane, W. S., and Voellmy, R. (2005) Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem 6, 4

49. Calderwood, S. K., Xie, Y., Wang, X., Khaleque, M. A., Chou, S. D., Murshid, A., Prince, T., and Zhang, Y. (2010) Signal Transduction Pathways Leading to Heat Shock Transcription. Sign Transduct Insights 2, 13-24

50. Singh, I. S., He, J. R., Hester, L., Fenton, M. J., and Hasday, J. D. (2004) Bacterial endotoxin modifies heat shock factor-1 activity in RAW 264.7 cells: implications for TNF-alpha regulation during exposure to febrile range temperatures. J Endotoxin Res 10, 175-184

51. Shopland, L. S., Hirayoshi, K., Fernandes, M., and Lis, J. T. (1995) HSF access to heat shock elements in vivo depends critically on promoter architecture defined by GAGA factor, TFIID, and RNA polymerase II binding sites. Genes Dev 9, 2756-2769

52. Ivaldi, M. S., Karam, C. S., and Corces, V. G. (2007) Phosphorylation of histone H3 at Ser10 facilitates RNA polymerase II release from promoter-proximal pausing in Drosophila. Genes Dev 21, 2818-2831

53. Guertin, M. J., and Lis, J. T. (2010) Chromatin landscape dictates HSF binding to target DNA elements. PLoS Genet 6

54. Dyson, M. H., Thomson, S., and Mahadevan, L. C. (2005) Heat shock, histone H3 phosphorylation and the cell cycle. Cell Cycle 4, 13-17

55. Calderwood, S. K., Mambula, S. S., and Gray, P. J., Jr. (2007) Extracellular heat shock proteins in cell signaling and immunity. Ann N Y Acad Sci 1113, 28-39

56. Sugisawa, N., Matsuoka, M., Okuno, T., and Igisu, H. (2004) Suppression of cadmium-induced JNK/p38 activation and HSP70 family gene expression by LL-Z1640-2 in NIH3T3 cells. Toxicol Appl Pharmacol 196, 206-214

57. Stathopoulou, K., Gaitanaki, C., and Beis, I. (2006) Extracellular pH changes activate the p38-MAPK signalling pathway in the amphibian heart. J Exp Biol 209, 1344-1354

58. Deak, M., Clifton, A. D., Lucocq, L. M., and Alessi, D. R. (1998) Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. Embo J 17, 4426-4441

59. Davie, J. R. (2003) MSK1 and MSK2 mediate mitogen- and stress-induced phosphorylation of histone H3: a controversy resolved. Sci STKE 2003, PE33

60. Park, G. Y., Joo, M., Pedchenko, T., Blackwell, T. S., and Christman, J. W. (2004) Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am J Physiol Lung Cell Mol Physiol 286, L956-962

61. Ono, K., and Han, J. (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12, 1-13

62. Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M., Palvimo, J. J., Nakai, A., and Sistonen, L. (2006) PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci U S A 103, 45-50

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

13

63. Hietakangas, V., Ahlskog, J. K., Jakobsson, A. M., Hellesuo, M., Sahlberg, N. M., Holmberg, C. I., Mikhailov, A., Palvimo, J. J., Pirkkala, L., and Sistonen, L. (2003) Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1. Mol Cell Biol 23, 2953-2968

64. Tetievsky, A., and Horowitz, M. (2010) Posttranslational modifications in histones underlie heat acclimation-mediated cytoprotective memory. J Appl Physiol 109, 1552-1561

65. Vabulas, R. M., Ahmad-Nejad, P., Ghose, S., Kirschning, C. J., Issels, R. D., and Wagner, H. (2002) HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 277, 15107-15112

66. De Nardo, D., Masendycz, P., Ho, S., Cross, M., Fleetwood, A. J., Reynolds, E. C., Hamilton, J. A., and Scholz, G. M. (2005) A central role for the Hsp90.Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors. J Biol Chem 280, 9813-9822

67. Gao, B., and Tsan, M. F. (2003) Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 278, 174-179

68. Tsan, M. F., and Gao, B. (2009) Heat shock proteins and immune system. J Leukoc Biol 85, 905-910

69. Asea, A. (2008) Heat shock proteins and toll-like receptors. Handb Exp Pharmacol, 111-127 70. Basu, S., Binder, R. J., Ramalingam, T., and Srivastava, P. K. (2001) CD91 is a common

receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14, 303-313 71. Vega, V. L., Rodriguez-Silva, M., Frey, T., Gehrmann, M., Diaz, J. C., Steinem, C.,

Multhoff, G., Arispe, N., and De Maio, A. (2008) Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol 180, 4299-4307

72. Wang, R., Kovalchin, J. T., Muhlenkamp, P., and Chandawarkar, R. Y. (2006) Exogenous heat shock protein 70 binds macrophage lipid raft microdomain and stimulates phagocytosis, processing, and MHC-II presentation of antigens. Blood 107, 1636-1642

73. Gastpar, R., Gross, C., Rossbacher, L., Ellwart, J., Riegger, J., and Multhoff, G. (2004) The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J Immunol 172, 972-980

74. Zheng, H., Nagaraja, G. M., Kaur, P., Asea, E. E., and Asea, A. (2010) Chaperokine function of recombinant Hsp72 produced in insect cells using a baculovirus expression system is retained. J Biol Chem 285, 349-356

75. Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L. (1998) Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665

FOOT NOTES *Supported by NIH grants GM069431 (ISS) and GM066855, HL69057 and HL085256 (JDH) and by VA Merit Review grants to ISS and JDH. 1To whom correspondence should be addresses: Ishwar S. Singh, Ph.D., Division of Pulmonary and Critical Care, University of Maryland School of Medicine, Rm. 311, Health Science Facility-II, 20 Penn St., Baltimore, MD 21201. Phone: 410-706-5507, FAX: 410-706-5508, Email:isingh@umaryland.edu 2The abbreviations used are ChIP, Chromatin Immunoprecipitation, FRT, febrile range temperature, HMGB1, high mobility group box 1, HSF1, heat shock factor-1, HSP, heat shock protein, PAMPS, pathogen-associated molecular patterns, PRR, pattern recognition receptors, TLR, toll-like receptor,

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

14

FIGURE LEGENDS FIGURE 1. Proinflammatory agonists augment hyperthermia-induced Hsp70 expression in RAW cells: A. RAW cells were incubated with or without 100 ng/ml LPS at 37°C or at 39.5°C for 2 or 4 h and Hsp70 mRNA was measured by real-time PCR, expressed as a ratio to GAPDH levels, and standardized to untreated 37°C baseline levels. Mean±SE of 4 experiments. * and † denote p<0.05 vs. No-LPS 37°C controls and No-LPS 39.5°C cells at the same time point, respectively. B, C. RAW cells were incubated with 100 ng/ml LPS, 0.5 µg/ml Pam3CSK4 (Pam3C), or 12.5 µg/ml poly IC (pIC) at 39.5°C for 6 h (B) or were exposed to HS at 42°C for 2 h, recovered at 37°C for 4 h (C), lysed, and immunoblotted for Hsp70 and β-tubulin; lane 1 is untreated 37°C control. D. A549 cells were incubated with or without 1 ng/ml IL-1β at 37°C or 39.5°C for 6 h, lysed, and immunoblotted for Hsp70 and β-tubulin. Immunoblots are representative of 4 independent experiments. FIGURE 2. Proinflammatory agonists induce HSF1 phsophorylation in RAW cells: A. RAW cells were incubated with 100 ng/ml LPS at 37°C for the indicated time, lysed and immunoblotted for HSF1 to analyze electrophoretic mobility shift. B, C. Lysates from RAW cells exposed to LPS for 30 min were incubated with or without (mock) shrimp alkaline phosphatase (SAP) for 30 min and then immunoblotted for HSF1 (B) or were resolved by 2D-gel electrophresis using a pH 3-10 IPG strip for the first dimension and a 10% SDS gel for the second dimension, then immunoblotted for HSF1 (C). D. RAW cells were treated with 100 ng/ml LPS, 12.5 ng/ml poly IC (pI:C), or 0.5 µg/ml Pam3CSK4 (Pam3C) with or without 20 µg/ml polymyxin B and lysates immunoblotted for HSF1. Lane 1 is untreated 37°C control. Immunoblots are representative of 4 independent experiments. FIGURE 3: LPS and FRT synergistically induce HSF1 recruitment to the HSPA1A promoter: A. RAW cells were incubated at 37° or 39.5°C with or without 100 ng/ml LPS and nuclear extracts analyzed for in vitro HSF1 DNA binding activity by EMSA. Lane 1 is probe alone. Lane 2 is nuclear extract from untreated 37°C RAW cells. B. For supershift and competition assays nuclear extracts from 39.5oC exposed cells in EMSA reaction were preincubated for 30 min on ice before addition of the radiolabeled probe with the following, 1) none, 2) IgG, 3) super-shifting anti-HSF1 antibody, 4) non-specific double-stranded oligonucleotide probe, and 5) 10-fold excess of unlabeled HSF1 probe. C. RAW cells were incubated at 37°C or 39.5°C with or without 100 ng/ml LPS for 60 min, formaldehyde cross-linked and HSF1 ChIP assay performed. DNA was quantified by real-time PCR using specific primers spanning the HSF1 binding site on the HSPA1A gene and presented as fold-enrichment compared with control IgG immunoprecipitates. Mean±SE, n=4, * and † denote p<0.05 vs 37°C cells and 39.5°C cells without LPS. FIGURE 4. LPS and FRT synergistically increase histone H3 phosphorylation and recruitment to HSPA1A chromatin: A, B. RAW cells were incubated with or without 100 ng/ml LPS at 37° or 39.5°C for 1 h, cross-linked with formaldehyde, and ChIP assay performed using anti-phospho-histone H3 (Ser-10) (A) or anti-histone H3 (B) antibody. Immunoprecipitated DNA was quantified by real-time PCR using specific primers spanning the HSF1 binding site on the HSPA1A gene and fold-enrichment compared with control IgG immunoprecipitates was calculated. Mean+SE, n=4, * and † denote p<0.05 vs untreated 37°C cells and untreated 39.5°C cells, respectively. C. RAW cells were incubated at 39.5°C with 100 ng/ml LPS for the indicated time and lysates immunoblotted for phospho- (p) and total (t) p38 and ERK. Lane 1 is untreated 37°C control cells. D. RAW cells were pre-incubated with ERK (U0126) or p38 (SB203580; SB) inhibitors for 30 min, then with 100 ng/ml LPS for 30 min at 39.5°C and lysates were immunoblotted for phosphorylated (p) and total (t) RSK and MK2. Lane 1 is from untreated 37°C control cells. Immunoblots are representative of 4 independent experiments. E. RAW cells were pretreated for 30 min at 37°C with 10 µM UO126 or SB203580-hydrochloride (SB) or DMSO, then stimulated with 100 ng/ml LPS for 2 h at 39.5°C and Hsp70 mRNA levels were measured by real-time PCR and expressed as fold-change vs. untreated 37°C control. F. RAW cells were pretreated with inhibitors as in panel C, then incubated with 100 ng/ml LPS at 37° or 39.5°C for 6 h and lysates were immunoblotted for Hsp70 and β-tubulin, quantified, and expressed as the Hsp70:β-tubulin ratio. Mean±SE, n=4. *, †, and ‡ denote p<0.05 vs. untreated (without

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

TLR agonists enhance hyperthermia-induced HSP synthesis.

15

LPS) 39.5°C control, cells treated with LPS and U0126 or DMSO, and similarly treated 37°C cells. G. RAW cells were pretreated with or without 10 µM SB203580-hydrochloride for 30 min at 37°C and phospho-histone H3 ChIP assay performed as describe above. * and † denotes p<0.05 vs. untreated 37°C cells and 39.5°C cells without SB203580, respectively. FIGURE 5. p38α knockdown reduces LPS-activated Hsp70 expression at FRT: RAW cells were transfected with scrambled negative control siRNA (scramb) or 50 or 100 pmoles of p38α (MAPK14) siRNA, and 48 h later either immunoblotted for p38α (A) or treated with 100 ng/ml LPS at 39.5°C for 6 h and immunoblotted for Hsp70 and β-tubulin (B). Ratio from four independent experiments were plotted (C). Data presented as mean+SE, *p<0.05. FIGURE 6. LPS synergizes with FRT and HS for extracellular release of Hsp70 from RAW cells: RAW cells were incubated with 0, 100, or 1000 ng/ml LPS at 37°C or 39.5°C for 6 h (A, E) or 24 h (B) or exposed to a 42°C HS for 2h and then incubated at 37°C for an additional 4 h (C, E) or 22 h (D). Cell culture supernatants were collected, cleared by centrifugation, and Hsp70 quantified by ELISA and presented as pg/ml (A to D) or LDH activity measured (6h) and presented as A490 of the reaction product (E). Data presented as mean±SE, n=4. * and † denote p<0.05 vs similarly treated 37°C cells and No-LPS 39.5°C or HS-exposed cells, respectively. FIGURE 7. LPS augments hyperthermia-induced Hsp70 expression in mouse lungs: A. Mice implanted with intraperitoneal thermistors were either housed at 25°C (normothermic; NT) or 36-37°C (hyperthermic; HT) ambient temperature and core temperature measured every 20 sec. The mean temperatures for each 2 h period were calculated and mean±SE shown (n=4); the two groups were different with p<0.05 by multifactorial AVOVA. B and C. Mice were intratracheally instilled with LPS or sterile PBS (control) and housed under normothermic or hyperthermic conditions for 24 h. Lungs were excised and homogenates immunoblotted for Hsp70 and expressed as a ratio to ß-actin (B) or lungs were lavaged and Hsp70 quantified by ELISA (C). Data are mean±SE (n=4). *, †, and § denote p<0.05 vs. PBS-treated NT controls, PBS treated HT mice, and LPS-treated NT mice respectively. FIGURE 8. Model of how fever, LPS, and Hsp70 interact to cause sepsis. Proposed model of sepsis in which LPS and fever initiate a positive feedback pathway through enhanced Hsp70 expression and release and subsequent increased TLR4 activation, Hsp70 expression and proinflammatory cytokine release.

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

AH

SP70

mR

NA

:GA

PDH

(fol

d vs

. 37°

C c

ont)

37°C 39.5°C

temperature 37°C 39.5°C stimulus none none LPS Pam3C pI:C

temperature 37°C HS stimulus none none LPS Pam3C pI:C

temperature 37°C 39.5°C stimulus none IL-1ß none IL-1ß

HSP70

HSP70

HSP70

ß-tubulin

ß-tubulin

ß-tubulin1 2 3 4 5

1 2 3 4

1 2 3 4 5

B

C

D

Figure 1

*

**†

*†

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

time (min) 0 5 10 15 30 60 120

1 2 3 4 5 6 7

1 2 3 4 5 6 7

HSF1 HSF1

A

C

D

B Stimulus none LPS Lysate none none SAP mock

1 2 3 4

No LPS

LPS

pH 3pH 10

stimulus none LPS pI:C Pam3Cpolymixin B - - + - + - +

Figure 2

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

Temperature 37°C 39.5°CTime (min) 0 30 60 30 60 30 60LPS p - + + - - + +

1 2 3 4 5 6 7 8

A C

B

HSF1

HSF1

supershift

HSF

1 fo

ld-e

nric

hmen

t

37°C 39.5°C 39.5°C +LPS

*

*†

Figure 3

1 2 3 4 5

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

0

0.3

0.6

0.9

1.2

1.5No LPS

LPS

Figure 4

phos

pho-

H3

fold

enr

ichm

ent

H3

fold

enr

ichm

ent

phos

pho-

H3

fold

enr

ichm

ent

37°C 39.5°C 37°C 39.5°C

*†Atime (min) 0 15 30 60p-p38

t-p38

p-ERK

t-ERK1

CB

37°C 39.5°C DMSO U0126 SB 39.5°C + LPS

**‡

‡

*‡

‡†

*

†

HSP

70:G

APD

H m

RN

A (f

old

vs. 3

7°C

)

E F

HSP

70:ß

-tubu

lin

none DMSO U0126 SB +LPSG

37°C 39.5°C

*

†

stimulus none LPS none none U0126 SBp-RSKt-RSK

p-MK2t-MK2

D

1 2 3 4

1 2 3 4

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

0

2

4

6 - LPS+ LPS*

scramb. 50 100p38a siRNA concentration (pM)

p38a

b-tubulinb-tubulin

HSP70

siRNA none scramb p38a 50pM 100pM

1 2 3 4 1 2 3 4 5 6

A

C

B

Figure 5

siRNA scramb p38a 50pM 100pM LPS - + - + - +

HSP

70:ß

-tubu

lin(f

old

chan

ge v

s. co

ntro

l)

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

LPS concentration (ng/ml) LPS concentration (ng/ml)

LPS concentration (ng/ml)

LPS concentration (ng/ml)

LPS concentration (ng/ml)

HSP

70 c

once

ntra

tion

(pg/

ml)

HSP

70 c

once

ntra

tion

(pg/

ml)

HSP

70 c

once

ntra

tion

(pg/

ml)

HSP

70 c

once

ntra

tion

(pg/

ml)

LDH

act

ivity

(A49

0)

A B C

D E

*†

*

*

* *

*

*†*†

*†

Figure 6

†*†

†

*†

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

Aco

re te

mpe

ratu

re (°

C)

time (h)

p < 0.05

B

HSP

70:ß

-tubu

lin ra

tio

mouse treatment

mouse treatment

*

§

HSP

70 c

once

ntra

tion

(pg/

ml)

C

Figure 7

*†

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

Figure 8

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from

Jeffrey D. Hasday and Ishwar S. SinghAditi Gupta, Zachary A. Cooper, Mohan E. Tulapurkar, Ratnakar Potla, Tapan Maity,

shock protein 70 expression and extracellular releaseToll-like receptor agonists and febrile-range hyperthermia synergize to induce heat

published online December 4, 2012J. Biol. Chem. 

  10.1074/jbc.M112.427336Access the most updated version of this article at doi:

 Alerts:

  When a correction for this article is posted• 

When this article is cited• 

to choose from all of JBC's e-mail alertsClick here

by guest on April 26, 2018

http://ww

w.jbc.org/

Dow

nloaded from